

**Chelsea and Westminster Hospital NHS Foundation Trust
Trust Medicines Committee**

Summary of Main Points from the Meeting held on the 14th of May 2012

2. Minutes and Summary Notes from last meeting

The Minutes and Summary notes were approved and will be circulated.

3. Matters Arising

The committee noted the matters arising from the previous meeting.

4. New Medicines Applications

Additions:

• **Dabigatran for atrial fibrillation – update following NICE TA 249**

Dabigatran has been NICE approved (March 2012) and recommended as an option for prevention of stroke and systemic embolism within its licensed indication. Rivaroxaban has received a positive final appraisal determination for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with risk factors. The committee reviewed the paper and agreed to continue restriction on prescribing of dabigatran and rivaroxaban to Dr Morgan and Dr Yarranton respectively, who are willing to continue further prescribing of these oral anticoagulants. The committee agreed that dabigatran or rivaroxaban should not be offered as 1st line to all patients that meet the licensed indication due to capacity for further prescribing and follow-up within the Trust while they remain on the 'NWL 'red list'.

Removals:

• Estradiol patches:

- o Fematrix 40 and 80mcg patches – removed from BNF

Ex-panel additions:

- Menopur 600units and 1200units multidose vials

The committee agreed the ex-panel addition of Menopur to the Formulary. Menopur 600units and 1200units are the same price as Menopur 75units, and are more cost-effective and more convenient for patients to use.

5. Medicines Management / Medicines Policy

• **Section 1 – Introduction**

The committee agreed:

Section 1.2.5 (Medication Safety) to be updated to include where medication incident reports are circulated and reviewed.

Section 1.3 (Medicines Policy Training) to be updated to reflect comments.

Section 1.4 (Review, Monitoring and Audit of the Medicines Policy) to be updated to include an audit of medicines storage being sent to the Trust Assurance Committee which reports to the Trust Board.

Section 1.5 (Accountability Structure) to be updated for medicines management.

• **C&W Opioid Prescribing Guide Medicines**

The committee deferred approval of the Opioid Prescribing Guide as there were various comments on the guideline which:

- requires revising and tailoring for the patient groups at C&W (currently written for medical students)
- requires consultation with opiate/palliative prescribers
- should refer to opioids on the C&W Formulary
- should be a similar format to other pocket guides within the Trust
- should have no reference of the industry company on the guideline

• **Medicines Committee Programme of Development 2012-13**

The committee noted the draft summary of the Medicines Committee agenda items and work planned. It was suggested to include in the forward plan for the year; CLAHRC updates, medicines reconciliation and discharge feedback, side-effects feedback, the new medicines service, NWL Formulary implementation, and e-chemo. DL to ask Clinical Pharmacists for any work planned e.g. in dementia, antibiotics and any planned audits.

6. NICE Guidance April 2012

• **TA249 – Atrial fibrillation – Dabigatran etexilate**

Discussed under agenda item 4.

• **TA250 – Breast cancer (advanced) – eribulin**

This guidance does not apply to C&W.

• **TA253 – Hepatitis C (genotype 1) – boceprevir**

NICE recommends boceprevir with peginterferon alfa and ribavirin as a possible treatment for genotype 1 chronic hepatitis C in adults with the earlier stages of liver disease. Boceprevir is on the C&W Formulary and no further action is required.

• **TA252 – Hepatitis C (genotype 1) - telaprevir**

NICE recommends telaprevir with peginterferon alfa and ribavirin as a possible treatment for genotype 1 chronic hepatitis C in adults with the earlier stages of liver disease. Telaprevir is on the C&W Formulary and no further action is required.

• **TA251 – Leukaemia (chronic myeloid, first line) – dasatinib, nilotinib and standard dose imatinib**

NICE does not recommend dasatinib for people with chronic myeloid leukaemia in the chronic phase who have not had treatment for chronic myeloid leukaemia before.

7. IVIG Update March 2012

**Chelsea and Westminster Hospital NHS Foundation Trust
Trust Medicines Committee**

There were 12 IVIG issues in April 2012, with 7 new requests:

- One was for Haemophagocytic syndrome (blue indication)
- One was for Pyoderma gangrenosum ulcer (grey indication) – the NWL individual funding request panel have approved funding for this case on the basis of exceptionality demonstrated and rarity, with no alternatives available
- Two were for Idiopathic thrombocytopenic purpura - adult (red indication)
- One was for Idiopathic thrombocytopenic purpura (< 16years) (red indication)
- One was for Kawasaki disease (red indication)
- One was for Myasthenia Gravis (blue indication)

8. Items for Noting

- **Regional Audit Report for Pharmacy Technical Services and Action Plan**

The committee noted the above report of an inspection visit by Regional Pharmacy QA to C&W Pharmacy Technical Services. The audit summary report states that the Unit is well managed with effective quality systems in place. A number of recommendations for improvement have been made and are reflected in the action plan. The committee noted the summary of progress (2 major deficiencies, 10 moderate deficiencies, and 9 minor deficiencies). DL to review and follow-up on the target completion dates for the recommendations.

- **Diclofenac Midwife Exemption**

The committee noted the above exemption, which was ratified at the Maternity Services Meeting on 21st March 2012.

- **Sonovue New Procedures Application**

The new procedures application was approved at the Trust's Quality Committee in April 2012. Sonovue is classed as a POM, and the committee noted its approval.

- **EU vs Poland Court Judgment Unlicensed Medicines**

The committee noted the ruling by the European Court which states that financial considerations do not qualify as a reason for choosing an unlicensed medicinal product when a licensed product is available.

- **Trust Antibiotic Steering Group Minutes October 2011**

The committee noted the above minutes.

- **Statin and ACEI vs ARB Audit April 2012**

The committee noted the report and adherence with the contract requirements. In April 2012, there was no newly initiated high cost statins or ARBs. It was suggested to share the audit results with the Medicines Management group.

9. Papers to go to the Trust Quality Committee

The following papers should be sent to the Trust Quality Committee

- Medicines Committee April 2012 Summary Notes
- Dabigatran and Rivaroxaban (Enclosure 4) paper

10. AOB

- **Medicines Committee representation on the NWL Formulary Panel**

The committee has nominated Dr David Hawkins to represent C&W Medicines Committee on the NWL Formulary panel, pending the agreement from HIV/GUM

11. Date of the next meeting

Monday 11th of June 2012 8.00 – 9.00 Board Room, Lower Ground Floor

Closing date for papers: Friday 18th of May 2012